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Purpose
Metastatic biliary tract cancer (mBTC) has a dismal prognosis. In this study, an independent
dataset of patients with mBTC was used to implement and validate a routine clinico-labo-
ratory parameter-based scoring model for risk group identification.
Materials and Methods
From September 2006 to February 2015, 482 patients with mBTC were assigned randomly
(ratio, 7:3) into investigational (n=340) and validation datasets (n=142). The continuous vari-
ables were dichotomized using a normal range or the best cutoff values determined using
the Contal and O'Quigley statistical methods. Following a Cox’s proportional hazard model,
the scoring model was derived by summing the rounded chi-square scores for the factors
identified by multivariate analysis. 
Results
The performance status (Eastern Cooperative Oncology Group 3-4), hypoalbuminemia 
(< 3.4 mg/dL), carcinoembryonic antigen ( 9 ng/mL), neutrophil-to-lymphocyte ratio 
( 3.0), and carbohydrate antigen 19-9 ( 120 U/mL) were identified as independent prog-
nosticators (Harrell’s C index, 0.682; integrated area under the curve, 0.653). Survival was
clearly correlated with the risk groups (low, intermediate, and high, 14.0, 7.3, and 2.3
months, respectively; p < 0.001). The prognosis was also discriminative in the validation
data set (median survival, 16.7, 7.5, and 1.9 months, respectively; p < 0.001). Chemother-
apy did not offer any survival benefits for high-risk patients. 
Conclusion
These proposed prognostic criteria for mBTC can facilitate accurate patient risk stratification
and treatment-related decision-making.
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Introduction
Biliary tract cancer (BTC) comprises a heterogeneous
group of tumors arising from the biliary tree-lining cells.
These tumors are classified further as gallbladder cancer, 
ampullary cancer, or cholangiocarcinoma. The latter type is 
divided phenotypically into intrahepatic and ductal cholan-
giocarcinomas (hilar and non-hilar) to emphasize the distinc-
tions between these clinically distinct cancers [1,2]. BTC is a
relatively rare malignancy in Western populations; approx-
imately 2,500 cases of cholangiocarcinoma and 5,000 cases of
gallbladder cancer occur annually in the USA, yielding an
average annual incidence of one case per 100,000 people. In
contrast, multiple independent studies have documented a
steady increase in the worldwide incidence of cholangiocar-
cinoma [3,4], and BTC is relatively common in Asian coun-
tries, including Korea, Japan, China, and India [5], with an
approximate incidence of six cases per 100,000 people [5,6].
In 2013, 5,283 patients were newly diagnosed with BTC and
3,783 related deaths were reported in Korea, where BTC is
the sixth-leading cause of cancer mortality. 
Few treatment options are available for advanced BTC. 
Although a complete surgical resection remains the only cur-
ative treatment option, few patients are candidates for a 
potentially curative resection at the time of presentation. BTC
is relatively chemo-/radio-resistant disease, and many 
patients are elderly and not healthy enough to tolerate 
aggressive treatment. Accordingly, these patients have dis-
mal outcomes with a median survival of < 1 year [7]. Cur-
rently, combination chemotherapy with cisplatin and
gemcitabine (Gem/Cis) is considered the standard first-line
palliative treatment, regardless of the primary tumor loca-
tion, which is based on the results from the ABC 02 trial [8].
On the other hand, the response rate to Gem/Cis is only 26%,
with a median overall survival (OS) of  11.7 months. In
other words, this regimen does not constitute an optimal
treatment [8]. Therefore, it is essential to estimate the prog-
nosis of a patient with metastatic BTC at the initial presenta-
tion, thus enabling patient individualization according to the
risk and facilitating treatment optimization.
To date, several reports have addressed the prognostic 
parameters associated with BTC. For example, lymph node
metastasis is a typical poor prognosticator for resectable BTC,
and laboratory analyses indicated that a high C-reactive pro-
tein level and neutrophil-to-lymphocyte ratio (NLR) are cor-
related with survival in patients with resectable cancer or
those receiving systemic chemotherapy. Despite this, few
prognostic studies have addressed metastatic disease at 
diagnosis [9-12]. Of these, the majority targeted predictions
after chemotherapy (particularly Gem/Cis). Although East-
ern Cooperative Oncology Group performance status (ECOG
PS), NLR or absolute neutrophil counts, hemoglobin, white
blood cell (WBC) counts, primary tumor location, and the
number of metastatic diseases have been proposed, the sig-
nificance of these factors is unclear. Most of these parameters
were identified using small sample sizes with inadequate sta-
tistical power, and their roles have rarely been confirmed 
independently. Another problem is the risk of bias when the
points of cutoff for the continuous variables are random,
leading to the use of different cutoff points across studies,
which imped a direct comparison between studies. Ulti-
mately, in a real-world clinical setting, the question of "which
patients to treat" should be answered prior to "which regi-
men to use," and that the answer to the former question 
requires the proposal of prognosticators that could discrim-
inate patients who might and might not benefit from treat-
ment.
Therefore, this paper presents the results of multivariate
analysis of routinely evaluated clinico-laboratory parameters
"at the time of initial diagnosis," to implement a scoring
model that could effectively identify the risk groups, and val-
idate the model in an independent dataset.
Materials and Methods
1. Patients
From September 2006 to February 2015, 623 patients were
diagnosed with metastatic BTC at Gangnam Severance Hos-
pital, Seoul, Korea. The diagnosis was made via a surgical
excision, tissue biopsy, or cytology. The inclusion criteria for
further analysis were as follows: (1) age > 18 years, (2) histo-
logically confirmed diagnosis of BTC, (3) metastatic disease
at the time of diagnosis or systemic recurrence after a cura-
tive resection, and (4) available electronic medical records
(including treatment information). 
The exclusion criteria were as follows: (1) widespread
brain or leptomeningeal metastasis, (2) synchronous metasta-
tic malignancies, (3) uncontrolled infection, active gastroin-
testinal bleeding, or other severe medical conditions, and (4)
follow-up loss or transfer to another hospital prior to the 
decisions regarding treatment (including diagnosis only).
Overall, 482 patients fulfilled these criteria and were further
analyzed (Fig. 1). Our institutional review board approved
this retrospective study and waived the requirement to 
obtain informed consent (3-2015-0318).
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2. Data collection
The following baseline data were recorded at the initial
presentation: age, sex, disease status (recurrent/metastatic),
primary tumor location (gallbladder, ampullary, or cholan-
giocarcinoma–intrahepatic or ductal), metastatic disease sites
(liver, peritoneal carcinomatosis, lung, bone, lymph nodes,
or others), ECOG PS, and body mass index (BMI). The hema-
tological and blood chemistry values included the WBC and
platelet counts as well as the hemoglobin, serum protein, 
albumin, blood urea nitrogen (BUN), aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), total bilirubin,
alkaline phosphatase (ALP), cholesterol, carcinoembryonic
antigen (CEA), and carbohydrate antigen 19-9 (CA 19-9) lev-
els. CEA was measured by a chemiluminescence immunoas-
say using UniCel DxI 800 immunoassay analyzer and 
CA 19-9 was measured by an electrochemiluminescence 
immunoassay using a Roche kit (Mannheim, Germany). The
NLR was calculated by dividing the absolute neutrophil
count by the absolute lymphocyte count, and the platelet-
to-lymphocyte ratio (PLR) was derived from the ratio of the
platelets to lymphocytes. 
Chest and abdomino-pelvic computed tomography (CT),
radionuclide bone scan, and 18F-fluorodeoxyglucose posi-
tron emission tomography were performed to evaluate the
distant metastasis. Radiological detection of peritoneal car-
cinomatosis relied on the following findings, which were
evaluated by an independent radiologist(s): thickening and
nodular enhancement of peritoneal reflections, multiple soft
tissue nodules, omental stranding and thickening (omental
cake), small bowel mesentery stranding and distortion, and
ascites, particularly if loculated. The presence of ascites was
inferred from the evidence of malignant cell detection in a
cytology examination or from suspicious fluid collection on
CT or ultrasonography.
3. Dataset allocation
For the prognostic scoring model, the patients were 
assigned randomly into the investigation or validation
dataset at a ratio of 7:3 using the primary tumor location
stratification factor. The scoring model derived from the 
investigational dataset was validated internally using three
methods, Harrell’s C-index, integrated area under the curve
(iAUC), and bootstrapping, followed by application to the
independent validation dataset [13]. 
4. Statistical analysis
The hematological and blood chemistry values were ini-
tially recorded as continuous variables and later transformed
to categorical variables according to the upper normal ranges
(WBC, hemoglobin, platelet, serum protein, albumin, BUN,
AST, ALT, bilirubin, ALP, and cholesterol) or the best cutoff
point (CEA, CA 19-9, NLR, and PLR). The latter were deter-
mined using the Contal and O’Quigley method, which cal-
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Fig. 1. Consort diagram of the enrolled patients. 
Recurrent/metastatic biliary cancer
(n=623)
Pathology confirmed biliary cancer
(n=606)
Follow-up patients (n=510)
Eligible patients (n=482)
Biopsy not confirmed or not 
  done (n=17)
Transferred to another center
  or follow-up refusal (n=96)
Wide spread and symptomatic central 
  nervous system metastasis (n=6)
Synchronous metastatic cancers (n=13)
Septic shock (n=4)
Massive gastrointestinal bleeding (n=3)
Hepatorenal syndrome (n=1)
Hepatic encephalopathy (n=1)
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Characteristic Total Investigation Validation p-value(n=482) dataset (n=340) dataset (n=142)
Age (yr)
< 67 235 (48.8) 163 (47.9) 72 (50.7) 0.58
 67 247 (51.2) 177 (52.1) 70 (49.3)
Sex
Male 281 (58.3) 201 (59.1) 80 (56.3) 0.573
Female 201 (41.7) 139 (40.9) 62 (43.7)
Disease status
Recurrent 158 (32.8) 117 (34.4) 41 (28.9) 0.238
Metastatic 324 (67.2) 223 (65.6) 101 (71.1)
ECOG
0-2 418 (86.7) 296 (87.1) 122 (85.9) 0.736
3-4 64 (13.3) 44 (12.9) 20 (14.1)
Primary site
Intrahepatic CC 123 (25.5) 87 (25.6) 36 (25.4) 1.00 
Hilar CC 79 (16.4) 56 (16.5) 23 (16.2)
Non-hilar CC 87 (18.0) 61 (17.9) 26 (18.3)
Gallbladder 146 (30.3) 103 (30.3) 43 (30.3)
Ampullary 47 (9.8) 33 (9.7) 14 (9.9)
BMI 22.8 (20.6-25.0) 22.7 (20.4-24.9) 23.2 (21.0-25.1) 0.223
Complete blood count 
WBC count (/µL) 7,090 (5,525-9,615) 7,070 (5,555-9,650) 7,130 (5,328-9,563) 0.881
Hemoglobin (g/dL) 12.2 (11.1-13.4) 12.1 (11.1-13.4) 12.3 (11.1-13.4) 0.771
Platelet (103/µL) 243 (189-319) 241 (186-314) 250 (200-326) 0.398
NLR 3.2 (2.0-5.8) 3.3 (2.0-5.7) 3.2 (2.1-6.1) 0.738
PLR 171 (122-251) 165 (120-234) 181 (123-275)
Blood chemistry profile 
Protein (g/dL) 6.9 (6.5-7.4) 6.9 (6.5-7.4) 7.0 (6.5-7.4) 0.804
Albumin (g/dL) 3.9 (3.4-4.3) 3.9 (3.4-4.3) 3.9 (3.4-4.3) 0.775
BUN (mg/dL) 14.7 (11.5-19.2) 14.8 (11.6-19.3) 14.4 (11.3-18.9) 0.671
AST (IU/L) 36 (22-75) 37 (23-81) 35 (22-68) 0.433
ALT (IU/L) 30 (17-74) 30 (17-72) 29 (18-76) 0.850
Bilirubin (mg/dL) 0.8 (0.5-3.4) 0.8 (0.5-3.6) 0.8 (0.5-2.7) 0.650
ALP (IU/L) 146 (89-321) 146 (88-321) 141 (91-312) 0.599
Cholesterol (mg/dL) 167 (134-198) 168 (134-194) 165 (132-202) 0.900
Tumor marker 
CEA (ng/mL) 3.6 (1.9-16.0) 3.2 (1.8-15.1) 4.2 (2.4-18.9) 0.056
CA 19-9 (U/mL) 160 (26-1,472) 166 (25-1,587) 145 (27-1,298) 0.567
Palliative Tx
No 148 (30.7) 106 (31.2) 42 (29.6) 0.809
Gem/Cis 168 (34.9) 120 (35.3) 48 (33.8)
Othersa) 166 (34.4) 114 (33.5) 52 (36.6)
Table 1. Patient characteristics in the investigation and validation datasets
Values are presented as number (%) or median (interquartile range). The Mann-Whitney U test was used for comparisons of
continuous values. ECOG, Eastern Cooperative Oncology Group; CC, cholangiocarcinoma; BMI, body mass index; WBC,
white blood cell; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; BUN, blood urea nitrogen; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; CA 19-9, car-
bohydrate antigen 19-9; Tx, treatment; Gem/Cis, combination chemotherapy with cisplatin and gemcitabine. a)Fluorouracil
or gemcitabine-based (excluding Gem/Cis) chemotherapy. 
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culates the maximum hazard ratio (HR) based on log-rank
statistics and estimates the best cutoff value [14]. 
The OS was defined as the time from the date of diagnosis
to death from any cause. Survival curves were generated
using the Kaplan-Meier method and compared using the log-
rank test. Univariate analysis was performed to determine
the association of the following prognostic factors with OS:
age, sex, disease status, ECOG PS, primary site, BMI, WBC
count, hemoglobin, platelet count, serum protein, albumin,
BUN, AST, ALT, bilirubin, ALP, cholesterol, CEA, CA 19-9,
NLR, and PLR. Subsequently, stepwise multivariate analysis
based on Cox’s proportional hazard model was performed
using the significant factors in univariate analysis. HRs, 95%
confidence intervals (CIs), and chi-square scores were 
obtained for all regressions. 
Using the investigation dataset, a risk scoring model was
devised by summing the rounded chi-square scores of inde-
pendent prognostic factors identified in the multivariate
analysis. Finally, patients were grouped into three risk
groups according to the risk scores: low risk, intermediate
risk, and high risk. The discriminatory power of this scoring
system was estimated using Harrell’s c-index [15] and an
iAUC. The latter was derived from time-dependent receiver
operating characteristics curve analysis [16,17]. Finally, this
Hyung Soon Park, Prognostic Model of Metastatic BTC
Fig. 2. Kaplan-Meier curves of overall survival for the investigation dataset (n=340): carcinoembryonic antigen (CEA) (A),
carbohydrate antigen 19-9 (CA 19-9) (B), neutrophil-to-lymphocyte ratio (NLR) (C), and platelet-to-lymphocyte ratio (PLR)
(D). 
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Investigation dataset Validation datasetCharacteristic
HR 95% CI p-value HR 95% CI p-value
Age (yr)
< 67 1 0.02 1 0.249
 67 1.311 1.043-1.649 1.231 0.865-1.754
Sex
Male 1 0.515 1 0.937
Female 0.926 0.735-1.167 1.014 0.713-1.443
Disease status
Recurrent 1 < 0.001 1 0.057
Metastatic 1.584 1.24-2.023 1.462 0.989-2.161
ECOG
0-2 1 < 0.001 1 < 0.001
3-4 4.499 3.205-6.316 5.276 3.102-8.972
Primary site
Intrahepatic CC 1 0.045 1 0.187
Hilar CC 0.802 0.563-1.144 0.834 0.479-1.451
Non-hilar CC 0.91 0.643-1.289 0.592 0.349-1.004
Gallbladder cancer 0.94 0.692-1.276 0.895 0.56-1.431
Ampullary cancer 0.514 0.331-0.8 0.519 0.255-1.057
BMI
 18.5 1 0.001 1 0.024
< 18.5 2 1.332-3.002 2.225 1.111-4.459
WBC count (/µL)
Normal (< 10,800) 1 < 0.001 1 < 0.001
Abnormal ( 10,800) 1.779 1.327-2.383 3.177 2.014-5.012
Hemoglobin (g/dL)
Normal ( 12) 1 0.005 1 0.209
Abnormal (< 12) 1.391 1.107-1.748 1.254 0.881-1.784
Platelet (103/µL)
Normal ( 150) 1 0.086 1 0.814
Abnormal (< 150) 1.375 0.955-1.98 0.935 0.535-1.634
Protein (g/dL)
Normal ( 6.9) 1 0.013 1 0.006
Abnormal (< 6.9) 1.337 1.064-1.681 1.635 1.149-2.325
Albumin (g/dL)
Normal ( 3.4) 1 < 0.001 1 0.011
Abnormal (< 3.4) 2.216 1.698-2.892 1.699 1.132-2.552
BUN (mg/dL)
Normal (< 23) 1 0.058 1 0.01
Abnormal ( 23) 1.401 0.988-1.988 1.956 1.178-3.25
AST (IU/L)
Normal (< 30) 1 0.151 1 0.176
Abnormal ( 30) 1.187 0.94-1.501 1.279 0.895-1.826
ALT (IU/L)
Normal (< 33) 1 0.773 1 0.237
Abnormal ( 33) 1.034 0.823-1.299 1.239 0.869-1.768
Bilirubin (mg/dL)
Normal (< 1.2) 1 0.435 1 0.198
Abnormal ( 1.2) 1.099 0.867-1.394 1.277 0.88-1.853
Table 2. Univariate analysis of the overall survival
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model was applied to the independent validation dataset. 
All statistical analyses were performed using PASW Sta-
tistics ver. 18.0 (SPSS Inc., Chicago, IL), SAS ver 9.4 (SAS 
Institute Inc., Cary, NC), and R ver. 3.2.4 (Institute for Statis-
tics and Mathematics, Vienna, Austria; http://www.R-pro-
ject. org). A p-value of < 0.05 was considered significant. 
Results
1. Baseline characteristics of investigational and validation
datasets
The investigational dataset included 340 patients with a
median follow-up duration of 9.3 months (range, 0.3 to 78.1
months) from the initial admission. Table 1 lists the baseline
demographics and clinico-laboratory parameters. The 
median age was 67 years, and a slight male predominance
was observed (59.1%). Regarding the primary tumor loca-
tion, intrahepatic, hilar, and non-hilar cholangiocarcinoma
affected 87 (25.6%), 56 (16.5%), and 61 (17.9%) patients, 
respectively. Gallbladder and ampullary cancer was diag-
nosed in 103 (30.3%) and 33 (9.7%), respectively. The CEA,
CA 19-9, NLR, and PLR cutoff values of 9 ng/mL, 120 U/mL,
3.0, and 150, respectively, were determined using the Contal
and O’Quigley method. 
Table 1 also lists the characteristics of the validation
dataset. The distributions of the parameters investigated did
not differ significantly between the investigation and valida-
tion datasets. 
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Investigation dataset Validation datasetCharacteristic
HR 95% CI p-value HR 95% CI p-value
ALP (IU/L)
Normal (< 123) 1 0.043 1 0.043
Abnormal ( 123) 1.27 1.007-1.6 1.439 1.011-2.05
Cholesterol (mg/dL)
Normal (< 139) 1 0.005 1 0.022
Abnormal ( 139) 1.437 1.114-1.854 1.586 1.068-2.353
CEA (ng/mL)
< 9 1 < 0.001 1 0.016
 9 1.812 1.414-2.321 1.604 1.094-2.353
CA 19-9 (U/mL)
< 120 1 < 0.001 1 0.441
 120 1.668 1.323-2.104 1.149 0.807-1.637
NLR
< 3 1 < 0.001 1 < 0.001
 3 2.04 1.616-2.575 2.96 2.042-4.29
PLR
< 150 1 < 0.001 1 0.057
 150 1.719 1.355-2.181 1.43 0.99-2.066
Palliative Tx
No 1 < 0.001 1 < 0.001
Gem/Cis 0.484 0.364-0.643 0.284 0.180-0.448
Othersa) 0.492 0.372-0.650 0.305 0.198-0.471
Table 2. Continued
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CC, cholangiocarcinoma; BMI, body
mass index; WBC, white blood cell; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotrans-
ferase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; NLR, neutrophil-
lymphocyte ratio; PLR, platelet-lymphocyte ratio; Tx, treatment; Gem/Cis, combination chemotherapy with cisplatin and
gemcitabine. a)Fluorouracil or gemcitabine-based (excluding Gem/Cis) chemotherapy. 
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2. Assessment of the prognostic factors
For the investigational dataset, the estimated median OS
duration was 9.3 months (95% CI, 8.2 to 10.4), and the CEA,
CA 19-9, NLR, and PLR cutoff points were all found to be
prognostic. In particular, the OS was significantly longer in
patients with a low CEA (10.9 months vs. high 6.0 months, p
< 0.001) and CA 19-9 levels (11.9 months vs. high 7.5 months,
p < 0.001), as well as those with a low NLR (13.5 months vs.
high 5.9 months, p < 0.001) and PLR (11.4 months vs. high
7.2 months, p < 0.001) (Fig. 2A-D). Regarding the tumor 
location, ampullary cancer was associated with a longer sur-
vival compared to other locations (14.1 months vs. gallblad-
der cancer 9.3 months; intrahepatic cholangiocarcinoma 8.4
months; non-hilar cholangiocarcinoma 8.7 months; hilar type
9.7 months).
The age, disease status, ECOG PS, primary tumor location,
BMI, WBC count, hemoglobin, serum protein, albumin, ALP,
and cholesterol had statistically significant associations with
the OS in univariate analysis (Table 2). In multivariate analy-
sis, including these 15 variables, a poor performance status
(ECOG 3-4), hypoalbuminemia (< 3.4 mg/dL), elevated CEA
( 9 ng/mL), high NLR ( 3.0), and elevated CA 19-9 ( 120
U/mL) remained independent factors associated with a poor
survival in forward stepwise analysis (Table 3). 
3. Inducement of prognostic model
The above-listed five independent prognostic factors were
used to derive a scoring system, in which scores of 0-8 were
calculated by summing the rounded chi-square scores of
these factors (Table 3): 2 (ECOG-PS  3)+1 (albumin < 3.4
g/dL)+1 (CEA  9 ng/mL)+1 (CA 19-9  120 U/mL)+3 (NLR
 7). These scores were used to categorize the patients into
three subgroups: (1) low-risk (score, 0-2; 147 [43.9%]), (2) 
intermediate-risk (score, 3-5; 145 [43.3%]), and (3) high-risk
(score, 6-8; 43 [12.6%]) (see S1 Table for a summary of the
baseline characteristics). The respective median OS durations
were 14.0 months (95% CI, 11.5 to 16.5), 7.3 months (95% CI,
5.6 to 9.0), and 2.3 months (95% CI, 0.1 to 4.6) (p < 0.001) 
(Fig. 3A), with corresponding 1-year survival rates of 55.9%,
30.1%, and 5.2%, respectively. The internally validated Har-
rell’s c-index was 0.682 (95% CI, 0.663 to 0.701), and the scor-
ing system iAUC was 0.654 (S2 Fig. A). In addition, boo-
tstrapping to predict the 24-month survival revealed consis-
tent results in the investigation dataset (S2 Fig. B).
For independent validation, the scoring model was applied
to another dataset, and risk group categorization was per-
formed, as described above, to yield 62 (44.3%), 58 (41.4%),
and 20 (14.3%) patients in the low-risk, intermediate-risk,
and high-risk categories, respectively; the corresponding 
median OS durations were 16.7 months (95% CI, 14.9 to 18.5),
7.5 months (95% CI, 3.8 to 11.2), and 1.9 months (95% CI, 1.5
to 2.3) (p < 0.001) (Fig. 3B). Harrell’s c-index was 0.722 (95%
CI, 0.677 to 0.767), and the scoring system iAUC was 0.632
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Table 3. Multivariate analysis of the overall survival and scoring index
Factor Chi-square score HR 95% CI p-value Score
ECOG performance status
0-2 1.00 0.001 0
3-4 10.5 2.10 1.34-3.28 +2
Albumin (g/dL)
 3.4 1.00 0.017 0
< 3.4 5.7 1.49 1.08-2.07 +1
CEA (ng/mL)
< 9 1.00 0.033 0
 9 4.5 1.35 1.02-1.78 +1
CA 19-9 (U/mL)
< 120 1.00 0.032 0
 120 4.6 1.32 1.02-1.70 +1
NLR
< 3 1.00 < 0.001 0
 3 14.5 1.64 1.27-2.11 +3
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA
19-9, carbohydrate antigen 19-9; NLR, neutrophil-lymphocyte ratio. 
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(S2 Fig. A). 
Further internal validation was conducted using the pri-
mary site data from the investigation dataset. The scoring
model was most reliable for non-hilar cholangiocarcinoma,
and least reliable for intrahepatic cholangiocarcinoma and
ampullary cancer (S3 Table).
4. Associations with treatment outcomes
In the investigational dataset, 234 patients (68.8%) under-
went palliative chemotherapy comprising Gem/Cis (n=120,
35.3%) or other regimens (n=114, 33.5%), including 5-fluo-
rouracil (5-FU) or gemcitabine-based chemotherapy with/
without palliative radiotherapy (5-FU monotherapy [n=33,
9.7%], 5-FU/platinum [n=50, 14.7%], 5-FU/adriamycin [n=5,
1.5%], 5-FU/gemcitabine [n=5, 1.5%], gemcitabine monother-
apy [n=13, 3.8%], and gemcitabine/oxaliplatin [n=8, 2.4%]).
On the other hand, 98 patients (28.8%) received the best sup-
portive care (BSC) and eight (2.4%) received palliative radio-
therapy for bone metastasis (n=3, 0.9%) or local control (n=5,
1.5%). Patients receiving Gem/Cis or other regimens had a
significantly longer survival than those who received BSC
(median OS, 11.0 months vs. 11.3 months vs. 4.0 months, 
respectively; p < 0.001). 
One hundred eighteen (80.3%) and 96 (66.3%) patients in
the low- and intermediate-risk groups received chemother-
apy, whereas only 18 high-risk patients (41.9%) consented to
chemotherapy. In the former group, old age, hypoalbumine-
mia, leukocytosis, and anemia were the determining factors
regarding the selection of BSC, whereas a young age was the
most important predictor of a preference for chemotherapy
in the high-risk group. Palliative chemotherapy (Gem/Cis or
other regimens) yielded a significant survival benefit in the
low- and intermediate-risk patients (median OS, 11.4 months
vs. 12.1 months vs. 4.8 months; p < 0.001) (Fig. 4A), whereas
the high-risk patients did not receive such benefits (median
OS, 4.3 months vs. 3.8 months vs. 1.1 months; p=0.105) 
(Fig. 4B). Similar results were observed in the validation
dataset (Fig. 4C and D). 
Discussion
To the best of the authors’ knowledge, this is the first study
to implement a prognostic scoring model for patients with
metastatic BTC at the time of the initial disease presentation.
This model might better indicate which patients would ben-
efit from treatment because given the relative rarity of BTC,
most previous studies enrolled subjects irrespective of the
primary location, disease extent (local or distant metastasis),
and disease status (recurrent or unresectable). Moreover,
many patients with BTC are quite malnourished and have a
poor general state due to the dual effects of malignancy and
obstructive jaundice. Because of this population heterogene-
ity, identification of the prognostic factors is crucial for clin-
ical trial design and stratification factor selection. 
Most studies included patients who received palliative
chemotherapy, whereas the proportions of patients receiving
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Fig. 3. Kaplan-Meier curves of overall survival according to the risk groups based on the prognostic prediction scores: low
risk, 0-2; intermediate risk, 3-5; and high risk, 6-8; investigation (A) and validation datasets (B).
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active chemotherapy was not high, leading to a small num-
ber of study samples and low statistical power. This study
showed that one clinical parameter (ECOG PS) and four lab-
oratory parameters (serum albumin, CEA, CA 19-9, and
NLR) affected the patient survival. ECOG-PS is a well-estab-
lished, robust prognosticator in a variety of cancers, includ-
ing BTC [9,11]. Although hypoalbuminemia is not a widely
accepted BTC parameter, it is a key component of the modi-
fied Glasgow Prognostic Score, which can predict the cancer
survival independently of the tumor site [12,18]. The pre-
treatment serum albumin levels provide useful prognostic
information [19] because albumin synthesis reflects malnu-
trition and tumor-related inflammation through the produc-
tion of cytokines, such as interleukin 6 [19]. A third of these
patients were identified as nutritionally at-risk upon admis-
sion, according to the Malnutrition Universal Screening Tool
(MUST), leading to the initiation of nutritional care plans
[20].
These results are comparable to those of McNamara et al.
[9], who reported the associations of a poor ECOG PS, low
albumin level, and high NLR with reduced survival in 
patients with BTC. On the other hand, that study included a
heterogeneous dataset that incorporated all the disease
stages (I-IV) and a wide range of treatments (curative surgery
Cancer Res Treat. 2017;49(4):1127-1139
Fig. 4. Kaplan-Meier curves of the overall survival according to palliative chemotherapy use in the investigation and vali-
dation datasets: low-intermediate-risk (A, C) and high-risk (B, D), respectively. Gem/Cis, combination chemotherapy with
cisplatin and gemcitabine.
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to palliative therapy), and found that the primary location,
stage, lack of surgery, and anemia were also associated with
survival. In contrast, McNamara et al. [9] identified ECOG
PS as the most significant prognostic factor; the NLR had the
biggest impact on survival in this study. NLR, a marker of
host inflammation, is a prognostic factor in several cancers.
The prognostic significance of NLR might be related to 
reduced immunocompetence or neutrophilia, which would
contribute to a tumor-promoting microenvironment charac-
terized by suppressed host immune surveillance. Further-
more, its significance might be attributable to either a
predisposition to chronic inflammation, a known risk factor
for cancer development, or cancer-associated inflammation,
which was also reported to be a key determinant of disease
progression in many cancers [9]. 
Previous clinical and population-based studies examined
the effects of various inflammatory factors on BTC develop-
ment [21-24]. In metastatic BTC, the large cancer cell burden
may lead to paraneoplastic production of myeloid growth
factors (e.g., granulocyte colony-stimulating factor), and con-
sequently, leukocytosis. Lymphocytes play a critical role in
the tumor defense by inducing immune-mediated cytotoxic
cell death; accordingly, lymphopenia in a metastatic setting
reflects the reduced immunocompetence and the effects of
lympholytic cytokines produced by cancer or host cells. 
Recent findings suggest that in cancer patients, lymphopenia
might arise from tumor-mediated lymphocyte destruction
and/or altered lymphocyte homeostasis [25]. Cancer-associ-
ated neutrophils also produce vascular endothelial growth
factor, matrix metallopeptidase-9, reactive oxygen species,
and arginase 1, which encourage tumor development and 
inhibit the functions of cytotoxic lymphocytes [26,27]. Inter-
estingly, a high PLR was not found to be significant in this
multivariate analysis, possibly because of the significant link
between NLR and PLR (correlation co-efficient value, 0.446;
p < 0.001). 
The markers, CEA and CA 19-9, are non-specific because
their expression may increase in response to extrahepatic 
obstruction from any cause, and their cutoff values are more
obscure in the context of metastatic BTC. Previous studies
usually adopted the median values or normal ranges to 
dichotomize these continuous variables; however, some of
the percentiles and averages were arbitrary and might not
reveal the true prognostic value of these variables [28]. 
Accordingly, the Contal and O’Quigley method, which 
selects a cutoff point that maximizes the model likelihood
only after evaluating all possible cutoffs, was implemented
and useful cutoff values of 9 ng/mL for CEA and 120 U/mL
for CA 19-9 were estimated in patients with metastatic BTC.
On the other hand, this study focused only on the dicho-
tomization of a continuous covariate, assuming that such 
dichotomization would be possible from a biological point
of view; however, more than one cutoff may exist in reality.
Furthermore, an ideal cutoff search would work within the
framework of a multiple regression model to eliminate the
potential influences of other prognostic factors. Nevertheless,
this study provides insights into some of the data and out-
come-oriented cutoff determination methods.
The retrospective study design introduced some limita-
tions with regard to interpreting the effects of the different
treatment regimens used in this study. Gem/Cis has been
available and accepted widely in Korea since 2011. Prior to
that, various monotherapies and doublet regimens that 
included 5-FU, gemcitabine, and platinum agents were used.
In addition, > 30% of patients failed to start first-line chemo-
therapy. In the low-risk group, 20% of patients refused che-
motherapy because of old age, poor nutritional status, and
combined inflammation; in contrast, > 40% of patients in the
high-risk group attributed their decision in favor of chemo-
therapy to their young age. This scoring system is expected
to allow more sophisticated treatment decisions. For exam-
ple, patients with a score of  2 could expect their survival to
be extended by up to 16 months with active chemotherapy
(Gem/Cis or other regimens), and these patients would be
candidates for more aggressive regimens or clinical trials. On
the other hand, high-risk patients (score  6) are unlikely to
benefit from chemotherapy. Nevertheless, it would be 
imprudent to conclude that chemotherapy is contraindicated
for this group because the survival curves are still separated
between chemotherapy and best supportive group, even
though statistical significance was not reached. This may be
related to the lack of power, in which only small number of
patients was included for analysis. Alternatively, monother-
apy could be a rational option, even though a prospective
evaluation will be needed. 
Regarding the intermediate group, patients treated with
chemotherapy had a median survival of 9.9 months, suggest-
ing that the general survival benefit of chemotherapy has not
been established clearly; still, chemotherapy yielded a signif-
icant difference in survival (9.9 months vs. without 4.2
months; p=0.006, log-rank test). Therefore, chemotherapy is
recommended for patients with a good clinical condition. On
the other hand, patients with general deterioration (ECOG
2) or insufficient biliary decompression will receive only
small benefits from chemotherapy, and its indications should
be considered carefully. Overall, these findings suggest that
the proposed scoring system could facilitate the selection of
the "right" patients for the "right" treatment plan. 
In this study, multiple internal validation analyses were
performed. The Harrell’s c-index (0.682), iAUC (0.654), and
bootstrapping showed that the proposed model possesses
meaningful risk-based patient discrimination power [29].
Given the rarity of BTC, validation studies involving inde-
pendent datasets are uncommon; internal validation metho-
VOLUME 49 NUMBER 4 October 2017  1137
dologies were considered to be insufficiently credible and it
is believed that the inclusion of an independent test set vali-
dation is the strength of the present study. Validation using
an independent set confirmed that this scoring system clearly
divided patients according to risk. On the other hand, there
was another limitation. Although the investigation and val-
idation datasets comprised independent populations, all 
patients were treated at a single center. Therefore, the pro-
posed scoring model needs to be assessed in an external val-
idation dataset to improve the robustness. 
In conclusion, a set of prognostic criteria were proposed to
determine the survival outcomes of patients with metastatic
BTC, which were validated independently. Specifically, this
system suggests cutoff values for the ECOG PS, albumin,
CEA, CA 19-9, and NLR, which were identified as independ-
ent prognostic factors. In addition, the prognostic scoring
system provides a rationale for the risk stratification of 
patients with metastatic BTC. Clinicians should find that this
system facilitates treatment-related decision making. 
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